Compounds > tx 402
Page last updated: 2024-11-10

tx 402

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-amino-2-quinoxalinecarbonitrile: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4736915
SCHEMBL ID1128621
MeSH IDM0489209

Synonyms (12)

Synonym
3-amino-quinoxaline-2-carbonitrile
3-amino-2-quinoxalinecarbonitrile
tx 402
tx402 cpd
3-aminoquinoxaline-2-carbonitrile
36597-16-7
AKOS006271939
SCHEMBL1128621
mfcd00456402
DTXSID90406097
kih 402
2-amino-3-cyanoquinoxaline

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"To evaluate the usefulness of continuous administration of hypoxic cytotoxins in terms of targeting acute hypoxia in solid tumours and the significance of combination with mild temperature hyperthermia (MTH) (40 degrees C, 60 min), the cytotoxic effects of singly or continuously administered tirapazamine (TPZ) and TX-402 were examined in combination with or without MTH in vivo."( The usefulness of continuous administration of hypoxic cytotoxin combined with mild temperature hyperthermia, with reference to effects on quiescent tumour cell populations.
Hori, H; Kinashi, Y; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Suzuki, M; Uto, Y, 2005)		0.33
" Further, the usefulness of mild temperature hyperthermia (MTH, 40 degrees Celsius, 30 min) combined with TX-2100 was also examined compared with MTH combined with the concurrent administration with its component drugs."( The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006)		0.33
" TX-2100 or both TX-402 plus BSH in combination with MTH or not was administered to SCC VII tumour-bearing mice intra-peritoneally."( The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006)		0.33
" In addition, MTH had a stronger sensitizing effect when combined with TX-2100 than with the concurrent administration of its components TX-402 and BSH on both the total and Q cell populations in solid tumours."( The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006)		0.33
"MTH was very effective in combination with the newly-developed TX-2100."( The usefulness of mild temperature hyperthermia combined with a newly developed hypoxia-oriented 10B conjugate compound, TX-2100, for boron neutron capture therapy.
Hori, H; Kinashi, Y; Maruhashi, A; Masunaga, S; Nagasawa, H; Nagata, K; Ono, K; Sakurai, Y; Suzuki, M; Uto, Y, 2006)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.14 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
bromodeoxyuridine
Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.		2.0210pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
quinoxalines
quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.		3.1350mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
quinuclidines
Quinuclidines: A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms and contains an amine group.		2.0310quinuclidines;
saturated organic heterobicyclic parent
zd 6126
[no description available]		2.0210
tirapazamine
Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.		2.4320aromatic amine;
benzotriazines;
N-oxide		antibacterial agent;
antineoplastic agent;
apoptosis inducer
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Ovary
[description not available]		02.1110
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		02.1110
Carcinoma, Epidermoid
[description not available]		02.7230
Cancer of Head
[description not available]		02.0210
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.7230
Head and Neck Neoplasms
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)		02.0210
Benign Neoplasms
[description not available]		02.0210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0210
Anoxemia
[description not available]		02.0310
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.0310
Hepatocellular Carcinoma
[description not available]		02.0310
Cancer of Liver
[description not available]		02.0310
Invasiveness, Neoplasm
[description not available]		02.0310
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0310
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0310